Boxer Capital Management LLC Purchases New Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX)

Boxer Capital Management LLC bought a new stake in Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 135,000 shares of the company's stock, valued at approximately $2,352,000. Boxer Capital Management LLC owned 0.25% of Bicara Therapeutics as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Jane Street Group LLC purchased a new position in Bicara Therapeutics during the 3rd quarter worth $309,000. Barclays PLC purchased a new stake in shares of Bicara Therapeutics in the third quarter valued at approximately $255,000. Geode Capital Management LLC purchased a new stake in shares of Bicara Therapeutics in the third quarter valued at approximately $1,239,000. SG Americas Securities LLC purchased a new position in Bicara Therapeutics in the fourth quarter worth $147,000. Finally, Spire Wealth Management purchased a new stake in Bicara Therapeutics during the fourth quarter worth about $31,000.

Bicara Therapeutics Stock Performance

BCAX traded down $0.50 during trading on Monday, reaching $14.00. The stock had a trading volume of 514,336 shares, compared to its average volume of 480,702. Bicara Therapeutics Inc. has a 1-year low of $8.91 and a 1-year high of $28.09. The stock has a 50 day moving average of $12.94 and a two-hundred day moving average of $15.85.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last issued its quarterly earnings results on Thursday, March 27th. The company reported ($0.39) earnings per share for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.08). Research analysts predict that Bicara Therapeutics Inc. will post -2.59 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on BCAX shares. Wells Fargo & Company started coverage on Bicara Therapeutics in a report on Thursday, April 17th. They set an "underweight" rating and a $8.00 price objective for the company. Stifel Nicolaus set a $48.00 target price on shares of Bicara Therapeutics in a research report on Thursday, March 27th. Wedbush reissued an "outperform" rating and set a $31.00 price objective on shares of Bicara Therapeutics in a research note on Thursday, March 27th. Cantor Fitzgerald restated an "overweight" rating and set a $13.01 price objective on shares of Bicara Therapeutics in a research report on Thursday, March 13th. Finally, HC Wainwright cut their target price on shares of Bicara Therapeutics from $45.00 to $44.00 and set a "buy" rating for the company in a research note on Monday, April 7th. One investment analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $32.43.

Bicara Therapeutics Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.